SCHEMBL30101362

SCHEMBL30101362

CCOC(=O)CCOC[C@H](C)Nc1cnn(COCC[Si](C)(C)C)c(=O)c1Cl

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 4/20 0.34
▸ ALDH1A1 P00352 4/20 0.34
▸ RAB9A P51151 4/20 0.34
▸ NPSR1 Q6W5P4 4/20 0.34
▸ S1PR2 O95136 3/20 0.34
▸ LMNA P02545 3/20 0.34
▸ HTT P42858 3/20 0.34
▸ S1PR4 O95977 2/20 0.34
▸ S1PR1 P21453 2/20 0.34
▸ HCRTR1 O43613 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ HSP90AA1 P07900 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ PKM P14618 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ TLR9 Q9NR96 1/20 0.34
▸ BRD4 O60885 2/20 0.33
▸ KAT2B Q92831 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21522042 0.89 KAT2B (0.35) NPC1ALDH1A1RAB9ANPSR1S1PR2
SCHEMBL21522552 0.87 TIPARP (0.39) CYP2C9TIPARP
SCHEMBL21522414 0.82 KAT2B (0.40) NPC1ALDH1A1RAB9ANPSR1S1PR2
SCHEMBL21522415 0.82 KAT2B (0.40) NPC1ALDH1A1RAB9ANPSR1S1PR2
SCHEMBL29841952 0.81 TIPARP (0.31) NPC1ALDH1A1RAB9AS1PR4S1PR1
SCHEMBL24954272 0.79 TIPARP (0.35) CYP2C9BRD4TIPARPDGAT1
SCHEMBL21521662 0.79 TIPARP (0.41) CYP2C9TIPARP
SCHEMBL21522340 0.79 TIPARP (0.41) CYP2C9TIPARP
SCHEMBL21521661 0.79 TIPARP (0.41) CYP2C9TIPARP
SCHEMBL21520779 0.78 TIPARP (0.31) NPC1ALDH1A1RAB9ACYP2C9MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS, INC. 2025-01-30 — — US disclosed
EP-4234551-A2 PYRIDAZINONES AS PARP7 INHIBITORS Ribon Therapeutics Inc. (US) 2023-08-30 — — EP disclosed
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS ANKURA TRUST COMPANY, LLC, AS COLLATERAL TRUSTEE 2023-06-22 — — US disclosed
EP-3788040-B1 PYRIDAZINONES AS PARP7 INHIBITORS RIBON THERAPEUTICS INC (US) 2023-04-12 — — EP disclosed
US-11566020-B1 Pyridazinones as PARP7 inhibitors RIBON THERAPEUTICS, INC. (US) 2023-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250034120-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 NPC1 4551/4885ALDH1A1 1033/4885RAB9A 4468/4885
US-11566020-B1 Pyridazinones as PARP7 inhibitors PARP2, PARP1, PARP4 NPC1 4551/4885ALDH1A1 1033/4885RAB9A 4468/4885
US-20230192664-A1 PYRIDAZINONES AS PARP7 INHIBITORS PARP2, PARP1, PARP4 NPC1 4551/4885ALDH1A1 1033/4885RAB9A 4468/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback